Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nBELLEVUE, WA, April 10 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY)\nannounced today that data from preclinical studies of PX-478, pharmacodynamic\nstudies of PX-12 and preclinical studies of PX-866 will be presented at the\nAnnual Meeting of the American Association for Cancer Research (AACR) in San\nDiego April 12-16, 2008.\n\n\nOncothyreon is currently conducting a Phase 1 clinical trial of PX-478 in\npatients with advanced metastatic cancer and a Phase 2 trial of PX-12 in\npatients with advanced pancreatic cancer. PX-866 is expected to enter a Phase\n1 trial in patients with advanced cancers in the second quarter of 2008.\n\n\nDetails regarding these abstracts are as follows:\n\nPX-478\n\n- Molecular-genetic image guided studies of the antitumor HIF-1alpha\n inhibitor PX-478 in combination with radiation\n Abstract No. 2566, Session: Novel Mechanisms of Drug Action\n Presentation: Monday, April 14, 2008, 2:55 p.m. to 3:10 p.m. P.T.\n\n- HIF-1alpha antagonism by PX-478 inhibits progression and spread of\n orthotopic human small cell lung cancer and lung adenocarcinoma in\n mice\n Abstract No. 1440, Session: mTOR/Akt/PI3K Inhibitors and\n Vascular/Hypoxia Targeting Agents\n Poster session: Sunday, April 13, 2008, 1:00 p.m. to\n 5:00 p.m. P.T.\n\nPX-12\n\n- Pharmacodynamic evaluation of plasma thioredoxin-1 for patient\n enrichment of PX-12 clinical trials\n Abstract No. 4453, Session: Molecular Signatures and Proteomic\n Biomarkers\n Poster Session: Tuesday, April 15, 2008, 1:00 p.m. to\n 5:00 p.m. P.T.\n\nPX-866\n\n- Cellular and in vivo activity of a new PI3K inhibitor PX-866 for\n treatment of human glioblastoma\n Abstract No. 3731, Session: Imaging in Preclinical and Clinical\n Therapeutics\n Poster Session: Tuesday, April 15, 2008, 8:00 a.m. to\n 12:00 p.m. PT\n\n- Identification of novel synergistic targets RACK-1 and galectin-1 for\n rational drug combinations with PI3 Kinase inhibitors using siRNA\n synthetic lethality screening\n Abstract No. 2761, Session: Signal Transduction and Therapeutics\n Poster Session: Monday, April 14, 2008, 1:00 p.m. to\n 5:00 p.m. P.T.\n\n- Phosphatidylinositol 3-kinase stimulates the proliferation of\n bronchioalveolar stem cells in mouse models of oncogenic K-ras-\n induced lung cancer\n Abstract No. 5408, Session: Stem Cells\n Poster Session: Wednesday, April 16, 2008, 8:00...

More updates from Cascade Copper Corp.